RM

Renu Mengi

Active Director Director DIN 03423326
DIN 03423326 First appointment Mar 2011 Primary industry Trading
Unlock full profile Investments · shareholding · contact details
Current companies 1 active board seats
Total affiliations 1 Since Mar 2011
Shareholding value •••• Premium profile

About Renu Mengi

Data last updated:

Renu Mengi is a Director at Keryx Pharmaceuticals Private Limited (since 2011). The company operates in Trading. Keryx Pharmaceuticals Private Limited reported revenue of ₹30.5 Lakh (FY 2025).

DIN 03423326
Primary Designation Director
Industry Trading
First Appointment 19 Mar 2011
Oldest Company Age 19 yrs
Largest company Keryx Pharmaceuticals Private Limited · ₹30.5 Lakh (FY 2025)

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director19 Mar 20112007₹30.5 Lakh (FY 2025)Active

Board colleagues of Renu Mengi

NameDINCompanyDesignation
Ajay Mengi03423304Keryx Pharmaceuticals Private LimitedDirector

Directorship timeline

Open interactive timeline →
Keryx Pharmaceuticals Private Limited
Premium access

Shareholding and investment profile for Renu Mengi

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Renu Mengi

Renu Mengi currently holds 1 directorship: Keryx Pharmaceuticals Private Limited (Director, since 19 Mar 2011, revenue ₹30.5 Lakh (FY 2025)).

Renu Mengi was first appointed on 19 Mar 2011 as Director at Keryx Pharmaceuticals Private Limited.

The current boards of Renu Mengi's companies include Ajay Mengi (Keryx Pharmaceuticals Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available